Last updated: February 24, 2026
Case Overview
Catalyst Pharmaceuticals filed patent infringement claims against Jacobus Pharmaceuticals related to the company's marketed drug, Firdapse (amifampridine). The case was filed in the District of Puerto Rico in December 2020 under docket number 3:20-cv-14590.
Catalyst alleges that Jacobus's marketing and sale of a generic version of Firdapse infringes on U.S. Patent No. 8,768,961, which claims methods of treating Lambert-Eaton myasthenic syndrome (LEMS) with amifampridine.
Patent Details
- Patent Number: 8,768,961
- Filing Date: August 6, 2010
- Issue Date: July 1, 2014
- Patent Scope: Claims cover methods of treating LEMS with oral amifampridine formulations, with specific method steps involving safe dosing and administration.
Key Allegations
- Jacobus is marketing its generic amifampridine product as a treatment for LEMS.
- The product infringes on Catalyst’s patent claims, particularly methods of administration and dosages.
- Catalyst claims that Jacobus's infringement damages its market exclusivity and revenue.
Legal Proceedings and Developments
Complaint and Initial Filing (December 2020)
Catalyst initiated patent infringement litigation asserting that Jacobus's generic product infringes the '961 patent.
Preliminary Injunction Motion
Catalyst filed a motion seeking an injunction to prevent Jacobus from marketing its generic version before patent validity is resolved. The motion highlighted that Jacobus’s product closely resembles Catalyst’s claimed methods.
Patent Validity and Patent Office Proceedings
The United States Patent and Trademark Office (USPTO) has pending inter partes review (IPR) petitions filed by Jacobus to challenge the validity of the '961 patent. These proceedings are ongoing, with decisions expected in 2023.
Discovery Phase (2022)
Parties exchanged technical and patent validity evidence. Catalyst presented multiple expert opinions supporting the patent's validity. Jacobus argued that the patent claims are obvious in light of prior art references.
Summary Judgment and Defenses
Jacobus has filed motions to dismiss or limit claims based on alleged patent invalidity due to prior art disclosures and obviousness grounds.
Current Status (2023)
The case remains in the pre-trial phase, with the court awaiting the resolution of the USPTO’s IPR proceedings and potential summary judgment motions.
Strategic Significance
- The patent validity decision remains critical; if invalidated, Catalyst’s market exclusivity ends.
- Jacobus’s IPR requests aim to nullify the patent to enter the market freely.
- Catalyst continues to assert that its patent claims are robust and enforceable.
Market and Commercial Impact
The outcome directly affects the availability of generic amifampridine for LEMS. Catalyst’s ability to enforce its patent influences market share, revenue projections, and potential licensing strategies.
Specifically, the case’s resolution could determine whether Jacobus will launch a generic version before the patent expiry in 2030.
Key Legal Points
- Patent infringement claims hinge on claims construction and prior art.
- Validity challenges revolve around obviousness, novelty, and patentable subject matter.
- The interplay between district court rulings and USPTO IPR decisions influences the enforceability of the patent.
Key Takeaways
- The case underscores the significance of patent protections in the rare disease drug market.
- Ongoing IPR proceedings are central to the litigation outcome.
- Settlement prospects remain unknown; litigation could extend into 2024.
FAQs
1. What are the main issues in Catalyst Pharmaceuticals v. Jacobus Pharmaceuticals?
The core issues involve patent infringement and the patent's validity, specifically whether Jacobus's generic product infringes Catalyst's patent claims and whether those claims are valid under patent law.
2. How does the USPTO Inter Partes Review impact the case?
The IPR proceedings are a key mechanism for challenging patent validity. An invalidation could nullify Catalyst’s patent, allowing Jacobus to market generics without infringing.
3. What are the risks for Jacobus if the patent is upheld?
If the patent remains valid, Jacobus faces injunctions or damages for infringement, delaying or preventing generic product launch.
4. When is a decision expected in the IPR proceedings?
Decisions are anticipated in late 2023, which could significantly influence the district court’s subsequent rulings.
5. What are the commercial implications of the case’s outcome?
Victory for Catalyst could extend patent protections into the late 2020s, preserving market exclusivity. A ruling invalidating the patent could open the market to widespread generic competition.
References
[1] U.S. Patent No. 8,768,961. (2014).
[2] Catalyst Pharmaceuticals, Inc. v. Jacobus Pharmaceuticals Company, Inc., 3:20-cv-14590, District of Puerto Rico.
[3] U.S. Patent and Trademark Office. (2022). Inter Partes Review Proceedings.
